Giorgia Guglielmi
Giorgia Guglielmi is a freelance science writer based in Basel, Switzerland. Specializing in life sciences, medicine, and the relationship between science and society, she has published numerous articles in outlets including Nature, Science, and Scientific American. She holds a PhD in biology from the European Molecular Biology Laboratory and a Master’s in Science Writing from the Massachusetts Institute of Technology. She has received recognition for her work, including the John Kendrew Award in 2020 and an ERC-funded FRONTIERS Media Fellowship in 2025. She has also led lectures and workshops on science communication at institutions such as Harvard University and the University of Zurich.
The findings of a recent study suggest that (S)-IBD3540 is a promising approach for treating IBD in people.
The findings reveal an important mechanism through which commensal microbes influence skin’s health. The results may also help to inform treatments for people with skin conditions.
A recent study introduces a novel technique for developing next-generation probiotics, achieved by enabling strictly anaerobic bacteria to tolerate oxygen exposure without compromising their potential beneficial properties.
This study highlights the potential risks associated with the use of nanoparticles in food production and processing.
The findings suggest that Dau-d4 can supplement current DPP4 treatment approaches for type 2 diabetes.
The findings of a recent study may help identify targets for the prevention or treatment of rheumatoid arthritis and other inflammatory conditions.
The findings of a recent study suggest that microbial consortia such as MET-2 may be effective strategies to keep intestinal pathogens and antibiotic-resistant organisms at bay.
The findings of a recent study uncover how gut microbes may contribute to trigger GVHD, suggesting potential targets for therapies.
Larger studies with longer follow-ups are needed to assess whether and how VMT influences neurodevelopment.
The findings show that bacterial metabolites can sensitize cancer cells to treatment with immunotherapy by boosting the expression of HLA class I molecules.
